241 related articles for article (PubMed ID: 30215633)
1. Oral small molecules for psoriasis.
Singh S; Armstrong AW
Semin Cutan Med Surg; 2018 Sep; 37(3):163-166. PubMed ID: 30215633
[TBL] [Abstract][Full Text] [Related]
2. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Yiu ZZ; Warren RB
Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
[TBL] [Abstract][Full Text] [Related]
3. Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
McAndrew R; Levin E; Koo J
J Drugs Dermatol; 2015 Aug; 14(8):786-92. PubMed ID: 26267722
[TBL] [Abstract][Full Text] [Related]
4. Current and future oral systemic therapies for psoriasis.
Kelly JB; Foley P; Strober BE
Dermatol Clin; 2015 Jan; 33(1):91-109. PubMed ID: 25412786
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Song GG; Lee YH
Clin Drug Investig; 2019 May; 39(5):421-428. PubMed ID: 30806969
[TBL] [Abstract][Full Text] [Related]
6. New systemic therapies for psoriasis.
Mansouri Y; Goldenberg G
Cutis; 2015 Mar; 95(3):155-60. PubMed ID: 25844781
[TBL] [Abstract][Full Text] [Related]
7. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
Mamolo C; Harness J; Tan H; Menter A
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Berekmeri A; Mahmood F; Wittmann M; Helliwell P
Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
[TBL] [Abstract][Full Text] [Related]
10. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
Di Lernia V; Bardazzi F
Drug Des Devel Ther; 2016; 10():533-9. PubMed ID: 26889081
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
[TBL] [Abstract][Full Text] [Related]
13. Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
Strober BE; Gottlieb AB; van de Kerkhof PCM; Puig L; Bachelez H; Chouela E; Imafuku S; Thaçi D; Tan H; Valdez H; Gupta P; Kaur M; Frajzyngier V; Wolk R
Br J Dermatol; 2019 Jan; 180(1):67-75. PubMed ID: 30188571
[TBL] [Abstract][Full Text] [Related]
14. Safety evaluation of apremilast for the treatment of psoriasis.
Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic development in psoriasis.
Sobell JM; Leonardi CL
Semin Cutan Med Surg; 2014 Jun; 33(4 Suppl):S69-72. PubMed ID: 25268599
[TBL] [Abstract][Full Text] [Related]
16. Do we need more psoriasis therapies?
Lebwohl M
Lancet; 2015 Aug; 386(9993):512-4. PubMed ID: 26051367
[No Abstract] [Full Text] [Related]
17. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Gupta AK; Cernea M; Lynde CW
Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
[TBL] [Abstract][Full Text] [Related]
19. Oral small molecules for the treatment of atopic dermatitis: a systematic review.
Mobasher P; Heydari Seradj M; Raffi J; Juhasz M; Atanaskova Mesinkovska N
J Dermatolog Treat; 2019 Sep; 30(6):550-557. PubMed ID: 30501539
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Kuo CM; Tung TH; Wang SH; Chi CC
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):355-362. PubMed ID: 29136293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]